Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.

With the sheen of inevitability now scuffed off the BIOSECURE Act, diplomatic efforts to reduce US dependence on Chinese APIs are increasing in prominence. And the power of the legislation itself could be determined by litigation about a video app.

The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.